Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. - Wikidata - wikimedia - TriplyDB

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

http://www.wikidata.org/entity/Q36362075

about

IgG4 Characteristics and Functions in Cancer Immunity Human IgG4: a structural perspective Structural characterization of a human Fc fragment engineered for lack of effector functions Structural Determinants of Unique Properties of Human IgG4-Fc Crystal structure of deglycosylated human IgG4-Fc Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease IgG subclasses and allotypes: from structure to effector functions.Transferrin-antibody fusion proteins are effective in brain targeting Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.A Case of IgG2 Heavy Chain Deposition Disease in a Patient with Kappa Positive Plasma Cell Dyscrasia.The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation.Novel IgG-Degrading Enzymes of the IgdE Protease Family Link Substrate Specificity to Host Tropism of Streptococcus Species The contribution of allergen-specific IgG to the development of th2-mediated airway inflammation Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.Advances in combating fungal diseases: vaccines on the threshold IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.Development of a specific system for targeting protein to metallophilic macrophages.Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization.Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus.Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.The role of B-cells in heart failure Heavy chain deposition disease: an overview.Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Preferentially immunoglobulin (IgG) subclasses production in primary Sjögren's syndrome patients.Mouse and human FcR effector functions.

P2860

Q26770244-DC60CAF0-F029-419D-88D9-BFA4576C60FC Q26779758-3550BBBE-D029-48B2-983F-CB9D4D613351 Q27650876-F1314EA6-F976-473B-AC43-37B4A87DF8FC Q27680566-E1CA8F49-BAFF-4FD5-A414-E977C3D18FB7 Q27684440-00E7E376-861F-40EA-8D9C-42FFBDE11C94 Q27702872-FF05D621-EF6B-4C1A-86B4-D776D8C206F8 Q28069362-BF12929B-A8BC-44EC-A4E2-E1DAA6B7E23D Q30363006-23651D78-D13B-4F61-A500-07EE3CF8C109 Q33293219-5B0BBB83-FDF6-4CA4-A850-C9253A46E6F6 Q33408733-CBA1876A-2317-4BC3-BEB6-6243B68D9641 Q33636882-94A3C48C-E97D-4E6E-8DFB-56C3D4B69225 Q33870167-7E25DC83-310C-4E52-9D57-49C0B01E287E Q34242001-F346E683-AA91-454F-AE4F-9D8463E9AC2F Q34368678-539FA3F0-A932-43D3-94FD-55307927ED21 Q34506062-2761542D-18F4-48B8-846F-59ED312CE696 Q34656882-FFC185FE-B2D8-4D10-BDCA-0DF296E8C7AE Q34958061-4DB37605-0707-4CB6-8A63-B9BB5DE85F3F Q35221593-841EE731-D01A-46DF-B3FC-81BC0167EA34 Q35767742-35FE556F-F0D1-43B0-AA0A-D10BE243126A Q36156532-2F34D6B0-EF7D-4118-8531-2ACF2E46F6E7 Q36165324-6BB44CFF-328A-4ACD-84B3-8216053492DA Q36361177-0726676A-B976-4028-A7B9-D8BC816EDB23 Q36363690-5CC42B3B-E4E6-4959-B3F6-D74E71DC8032 Q36406460-918107DF-B30A-47F9-AA83-DE33588B454D Q36417907-3F7646CA-C634-4D82-BDED-FDFBACC8BC02 Q36513475-08738B2C-994C-49B2-AEFB-BEB57AEC75D3 Q36604283-57DF424F-D169-44F3-9E09-47170E11080E Q36645847-1D1EA6C3-87A9-4F4F-AE53-A8271407908C Q36688075-A0AB4903-0F46-4ACF-AEA1-743484374F36 Q36728029-9F8C0D9B-EFE9-40EC-918E-301D88CCE2F0 Q37032625-ED87C87B-124B-448E-9BC3-DCE660CA0E7F Q37088489-FC19C1AC-8DA5-4AE0-BA23-C207777F9074 Q37202064-0BCEA6D5-AE7D-48CC-A7DC-43FC4EDDA994 Q37452067-485F0AD7-700E-4FD5-87A1-75DA4724B5A3 Q37590820-E1EED64C-9E30-4111-AEAC-7FA8100CC8F9 Q38091933-51D40CB5-DB93-48C3-996B-A85E235E8396 Q38104996-AA041DF6-8DB0-4F64-A4DE-8017FC2420F0 Q38308978-BE3E0E1D-BEE5-4B5A-8CA6-76713EB4F456 Q38407400-E996D52F-06DB-4C49-B4B0-D5D4C5DD8C4B Q38615349-980E4129-C7BF-474F-A667-052F6BCCC7D4

P2860

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

http://www.wikidata.org/entity/Q36362075

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年学术文章

@wuu

1993年学术文章

@zh-cn

1993年学术文章

@zh-hans

1993年学术文章

@zh-my

1993年学术文章

@zh-sg

1993年學術文章

@yue

1993年學術文章

@zh

1993年學術文章

@zh-hant

name

Structural features of human i ...... nces in complement activation.

@ast

Structural features of human i ...... nces in complement activation.

@en

type

label

Structural features of human i ...... nces in complement activation.

@ast

Structural features of human i ...... nces in complement activation.

@en

prefLabel

Structural features of human i ...... nces in complement activation.

@ast

Structural features of human i ...... nces in complement activation.

@en

P1433

Q36362075-2C890348-6D29-4FE2-9201-EBCAA759CE59

P1476

Q36362075-2426D6C1-BEFF-4CC0-A94A-9BCB198AB49D

P2093

Q36362075-4B3129F4-D7A0-44EE-B2D4-139E116B98F8

Q36362075-5415B23E-F420-4572-8869-891000695D5C

Q36362075-78A68105-C9CD-484B-AD53-74AD82DE91B3

P2860

Q36362075-02B85352-18C0-4DDA-A067-714303465949

Q36362075-0C0DFD09-DC8C-419C-9639-688E9B2D1576

Q36362075-1938E848-08F3-4FDE-81DC-E478C1BF3359

Q36362075-23AC8DD1-ACCE-4435-B6D6-72AF17937DD0

Q36362075-279D6ED1-F5C1-46F9-BCB7-8CF0DBEA9E55

Q36362075-67D8BCFF-6834-4141-86FC-BDA491B6C901

Q36362075-823F9BFA-B598-4CDC-BFD1-F64D115621A2

Q36362075-856B30AA-2977-44E4-9995-C1FE2728769C

Q36362075-8A144E32-6901-4019-95C2-2A5EBD212A0E

Q36362075-8A622D34-6326-4520-9688-5402582488BB

P304

Q36362075-373C64EC-4B69-4851-8C0F-867BCA2CEF1C

P31

Q36362075-2420AB58-2E56-47D8-BECA-74E13B391315

P356

Q36362075-C993DB70-6303-4251-A218-C1CFACC53A8B

P407

Q36362075-CD2F6A03-5FA1-4B46-9B9B-198273D0D4C4

P433

Q36362075-94632C9F-67D8-40E8-ABE6-4AE529DDBAB4

P478

Q36362075-C4916659-A92B-441C-A990-064C8AE00DE7

P577

Q36362075-4125B94D-6197-4015-9AD9-8F0184A61E11

P5875

Q36362075-A4E74245-871C-493D-BB71-E91D31E144FF

P698

Q36362075-E6CDA85F-D76A-4FDE-B973-9DCD8340FC25

P932

Q36362075-57E2C99D-50A6-4D18-812B-A5C2F29E1E3A

P356

P1433

Journal of Experimental Medicine

P1476

Structural features of human i ...... nces in complement activation.

@en

P2093

M H Tao

http://www.w3.org/2001/XMLSchema#string

R I Smith

http://www.w3.org/2001/XMLSchema#string

S L Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

In vitro antibodies: strategies for production and application.

Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.

Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.

Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.

Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Localization of the binding site for the human high-affinity Fc receptor on IgG.

Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.

P304

661-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.178.2.661

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P577

1993-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277489932

http://www.w3.org/2001/XMLSchema#string

P698

8340761

http://www.w3.org/2001/XMLSchema#string

P932

2191116

http://www.w3.org/2001/XMLSchema#string